Search
for

    GlossaryTocilizumab (Actemra)

    medication that inhibits IL-6 receptor to reduce inflammation

    Tocilizumab, also known by the brand name Actemra, is a medication that targets the interleukin-6 (IL-6) receptor, which plays a role in the body's immune response. It is commonly used to treat autoimmune conditions such as rheumatoid arthritis and has also been explored for use in managing severe cases of COVID-19. By inhibiting IL-6, Tocilizumab helps reduce inflammation and modulate the immune system.

    Related Terms

    Learn

    0 / 0 results
    — no results

    Research

    5 / 7 results
      Drug News

      research Drug News

      July 2017 in “​​​​​​​​​​​​​​Nursing2023”
      Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
      Adverse Effects and Drug Interactions of Biologic Agents

      research Adverse Effects and Drug Interactions of Biologic Agents

      March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry”
      Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
    View more "actemra" in research →

    Community Join

    0 / 0 results
    — no results